229 RESULTS
RESEARCH NEWS 2019-11-08 Research News Researchers are searching for ways to dampen harmful inflammation and boost microglial phagocytosis in the Alzheimer’s brain. In the November 4 Proceedings of the National Academy of Sciences, researchers led by Hee Kyung Jin and Jae-sung Ba
RESEARCH NEWS 2019-11-22 Research News Microglia have been firmly linked to amyloid plaques, but scientists are only beginning to examine their relationship to tau tangles. In the November 20 Nature, Michael Heneka and colleagues at the German Center for Neurodegenerative Disease
CONFERENCE COVERAGE 2019-12-13 Conference Coverage There was a new feeling in the air at the 12th Clinical Trials on Alzheimer’s Disease conference. It felt good: After decades of failure, the field might finally be turning a corner. The renewed optimism at the meeting, held December 4
RESEARCH NEWS 2020-01-23 Research News In 2018, researchers created a stir with a multi-network analysis of postmortem tissue that suggested viruses—particularly human herpes—might disrupt molecular pathways in the brains of Alzheimer’s disease patients. Now, researchers led by S
COMMUNITY NEWS 2020-03-27 Community News “Do what you can, with what you have, where you are.” Theodore Roosevelt. Globally the story is the same almost everywhere. Scientists are in lockdown, most staying at home as skeleton crews tend to the most crucial experiments and valuable
CONFERENCE COVERAGE 2020-04-10 Conference Coverage Against classical music and visual backdrops evoking Vienna, where the second AAT-AD/PD conference was to be held, the meeting instead unfolded Netflix-style. In this surreal age of COVID-19, the conference organizers dropped five days
RESEARCH NEWS 2020-05-09 Research News ApoE4 weakens the blood-brain barrier in the hippocampus, and in this way takes its toll on cognition, according to a study published April 29 in Nature. Researchers led by Berislav Zlokovic of the University of Southern California in Los An
RESEARCH NEWS 2020-05-22 Research News Many research groups study tau misfolding and propagation using in vitro models, but interpreting findings from artificial systems can be dicey. In a preprint on bioRxiv, researchers led by Eckhard Mandelkow at the German Center for Neurodeg
RESEARCH NEWS 2020-01-17 Research News Transgenic mice fail to capture many aspects of Alzheimer’s disease, and a new transcriptional study lays bare one reason. Brain cells in the two species, it turns out, respond quite differently to amyloidosis. In the January 13 Nature Medic
RESEARCH NEWS 2019-06-22 Research News In Alzheimer’s disease, blood flows sluggishly through the brain, partly because Aβ provokes small blood vessels to constrict. In the June 20 Science, researchers led by David Attwell at University College London blame this on pericytes, tin
RESEARCH NEWS 2019-07-12 Research News The Alzheimer’s field was dealt another body blow yesterday with the announcement of a premature end to testing of Novartis/Amgen’s BACE inhibitor CNP520, aka umibecestat, in two Phase 2/3 trials. Part of the Alzheimer’s Prevention Initiativ
CONFERENCE COVERAGE 2019-07-25 Conference Coverage Scientists are becoming more nuanced in how they use amyloid scans—not just to detect the presence of Alzheimer’s pathology, but also to pinpoint disease stage. At this year’s Alzheimer’s Association International Conference, held July
RESEARCH NEWS 2019-08-23 Research News Microglia in the brain assume a dizzying array of states. Now researchers led by Tony Wyss-Coray at Stanford University, Palo Alto, California, describe a new one: lipid droplet-accumulating microglia (LAM). These lipid-stuffed cells resembl
RESEARCH NEWS 2019-08-23 Research News Mounting evidence suggests midlife hypertension negatively affects late-life cognition and that treating it could help. Three new papers support this idea. In the August 20 Lancet, researchers led by Marcus Richards, Nick Fox, and Jonathan S
RESEARCH NEWS 2019-09-13 Research News Marking the fall of the only remaining BACE inhibitor currently being tested for AD, Biogen and Eisai announced today the discontinuation of two Phase 3 studies of elenbecestat in people with mild cognitive impairment and mild AD. The compa
